Our investigation revealed that the tumor-driver potential of gain-of-function mutant FGFR2 depends on ADAM17-mediated MAPK activation, while the overexpression of loss-of-function FGFR2 mutants showed only minimal tumorigenicity in the absence of other driver alterations in cell-based assays. This evidence concerns the gene ADAM17 and neoplasm.